MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer
Abstract
No abstract available
Comprehensive cancer centre Antoine Lacassagne |
Camille Dumont : Connect in order to contact the contributor
https://inserm.hal.science/inserm-04527070
Submitted on : Friday, March 29, 2024-4:42:24 PM
Last modification on : Wednesday, July 24, 2024-2:43:36 PM